ABSTRACT
Recently, the results of a multi-institutional, prospective trial to investigate the therapeutic efficacy of the Medtronic Inspire I hypoglossal nerve stimulation system for OSA were reported (14). The system was implanted in eight middle-aged, moderately overweight men with moderate to severe OSA during rapid eye movement (REM) and non-REM (NREM) sleep. Nightly unilateral hypoglossal nerve stimulation was initiated at 4 weeks after system implantation. These patients initiated nightly electrical stimulation with a self-controlled programming unit. A preset delay in system activation allowed the patients to fall asleep before the start of electrical stimulation.
